References

For patients, please use the following contact information:

  1. Navarro-Sarabia F, Coronel P, Collantes E, Navarro FJ, de la Serna AR, Naranjo A, Gimeno M, Herrero-Beaumont G; AMELIA study group. A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry- over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis. 2011;70: 1957-62.

  2. GenVisc 850 Package Insert

  3. FDA summary of safety and effectiveness data (SSED). GenVisc® 850. http://www.accessdata.fda.gov/cdrh_docs/pdf14/p140005b.pdf. Accessed April 17, 2018.
† The Adant® formulation is approved in 63 countries outside the US. Adant is manufactured by TEDEC-MEIJI FARMA and is authorized to be marketed and distributed under the trademark GenVisc850.

Adant is a registered trademark of TEDEC-MEIJI FARMA. GenVisc 850 is a registered trademark of OrthogenRx, Inc.